Eswatini

Population 2017: 1.4 million

Estimated TB burden*, 2017
- Mortality (excludes HIV+TB): 0.14 (0.09–0.21) per 100,000 population
- Mortality (HIV+TB only): 0.6 (0.43–0.81)
- Incidence (includes HIV+TB): 4.2 (3.2–5.3)
- Incidence (HIV+TB only): 2.9 (1.9–4.2)
- Incidence (MDR/RR-TB)**: 0.34 (0.24–0.46)

Mortality (excludes HIV+TB): 0.14 (0.09–0.21) per 100,000 population
- Male: 0.15 (0.1–0.21)
- Female: 0.12 (0.08–0.17)

Mortality (HIV+TB only): 0.6 (0.43–0.81)
- Male: 0.65 (0.42–0.91)
- Female: 0.35 (0.19–0.58)

Incidence (includes HIV+TB): 4.2 (3.2–5.3)
- Male: 4.1 (3.1–5.3)
- Female: 4.4 (3.2–5.9)

Incidence (HIV+TB only): 2.9 (1.9–4.2)
- Male: 2.8 (1.7–3.9)
- Female: 3.0 (1.8–4.4)

Incidence (MDR/RR-TB)**: 0.34 (0.24–0.46)
- Male: 0.34 (0.25–0.46)
- Female: 0.35 (0.24–0.47)

Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Total</th>
<th>Females</th>
<th>Males</th>
<th>Male/Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>0.87</td>
<td>0.37</td>
<td>0.50</td>
<td>0.51</td>
</tr>
<tr>
<td>&gt;14 years</td>
<td>1.13</td>
<td>0.40</td>
<td>0.73</td>
<td>1.81</td>
</tr>
<tr>
<td>Total</td>
<td>1.89</td>
<td>0.77</td>
<td>1.06</td>
<td>1.32</td>
</tr>
</tbody>
</table>

TB case notifications, 2017
- Total cases notified: 3 544
- Total new and relapse: 3 367
- % tested with rapid diagnostics at time of diagnosis: 86%
- % with known HIV status: 94%
- % pulmonary: 87%
- % bacteriologically confirmed among pulmonary: 74%

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2017: 80% (63–100)
- TB patients facing catastrophic total costs: 0%
- TB case fatality ratio (estimated mortality/estimated incidence), 2017: 0.18 (0.12–0.25)
- Patients with known HIV-status who are HIV-positive: 2 191 (69%)
- % on antiretroviral therapy: 94%

Drug-resistant TB care, 2017
- New cases: 240
- Previously treated cases: 2 363
- Total number***: 2 603

Laboratory-confirmed cases
- MDR/RR-TB: 203
- XDR-TB: 4

MDR/RR-TB cases tested for resistance to second-line drugs: 172

Patients started on treatment ****
- MDR/RR-TB: 208
- XDR-TB: 10

Treatment success rate and cohort size
- New and relapse cases registered in 2016: 83% (3 403)
- Previously treated cases, excluding relapse, registered in 2016: 70% (196)
- HIV-positive TB cases registered in 2016: 83% (2 369)
- MDR/RR-TB cases started on second-line treatment in 2015: 68% (305)
- XDR-TB cases started on second-line treatment in 2015: 75% (8)

TB preventive treatment, 2017
- % of HIV-positive people (newly enrolled in care) on preventive treatment: <1%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 7.4% (6.8–8.2)

TB financing, 2018
- National TB budget (US$ millions): 12
- Funding source: 14% domestic, 86% international, 0% unfunded

RANGES REPRESENT UNCERTAINTY INTERVALS
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed